Greenland Mines (GRML)
Explores Greenland minerals alongside a biotech program for ALS.
Something off on this page? Send us feedback.
Mining exploration at the Skaergaard Project in southeast Greenland sits alongside a biotechnology division centered on KLTO-202 for ALS. The company holds a controlling interest in Skaergaard while pursuing an early-stage, two-division strategy.
Operating two early-stage divisions, mining focuses on exploration and development of the Skaergaard Project in southeast Greenland, while biotechnology centers on KLTO-202 for amyotrophic lateral sclerosis. The common stock trades on Nasdaq under GRML. The Greenland Mines acquisition gave the company a controlling interest in Skaergaard and an option on the remainder.
Planned acquisition of the Sarfartoq rare-earth project remains subject to closing conditions and Greenland government approval. Execution relies on two full-time employees and consultants as the company advances the mineral-exploration interest and biotech program. This structure combines an exploration-stage mineral business with a therapeutic program in one listed issuer.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.3M · Total debt $298.0K · Total assets $65.0M · Shareholders' equity $57.9M
- Revenue
- $0
- Operating income
- −$5.5M
- Net income
- −$3.7M
No dividends on record.
| Insiders | 4.31% | 129.7K shares | |
|---|---|---|---|
| 4 holders · as of Aug 25, 2026 | |||
| Other | 95.69% | 2.88M shares | |
| remainder | |||
3.01M company shares as of Aug 24, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jeff LeBlancInsiderofficer: Chief Financial Officer | 3.67% | 110,406 | filed Aug 25, 2026 |
Jon McGarityInsiderdirector | 0.37% | 11,026 | filed Jul 20, 2026 |
Jason David SawyerInsiderdirector | 0.16% | 4,800 | filed Jul 23, 2026 |
Riad Hussein El-DadaInsiderdirector | 0.12% | 3,500 | filed Jun 26, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Jeff LeBlanc | officer: Chief Financial Officer | +14,000 | $9.72 |
| Jul 22, 2026 | Jason David Sawyer | director | +240,000 | $0.2331 |
| Jul 20, 2026 | Jon McGarity | director | +140,000 | $0.1773 |
| Jul 16, 2026 | Jeff LeBlanc | officer: Chief Financial Officer | +1,400,000 | $0.1752 |
| Jun 25, 2026 | Riad Hussein El-Dada | director | −175,000 | $0.2317 |
- Platinum Group Metals
Develops a large South African palladium and platinum project
- Sibanye Stillwater (ADR)
Major producer of platinum-group metals across South Africa and the US
- Critical Metals
Advances the Tanbreez heavy-rare-earth project in Greenland
- MP Materials
Integrated U.S. producer of NdPr and rare-earth magnets
- Ionis Pharmaceuticals
Genetic-medicine programs for ALS, including QALSODY
- Clene
Late-stage CNM-Au8 program for amyotrophic lateral sclerosis
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Greenland Mines | $13.52 | +45.43% | $28.4M | — | — | — | — |
| Platinum Group Metals | $1.42 | +1.07% | $180.3M | — | — | — | — |
| Sibanye Stillwater (ADR) | $11.27 | +1.42% | $7.88B | 8.7 | — | 0.8 | +80.5% |
| Critical Metals | $9.02 | −3.01% | $1.37B | — | — | — | +57.8% |
| MP Materials | $50.65 | +1.19% | $8.90B | — | 151.9 | 29.1 | +89.0% |
| Ionis Pharmaceuticals | $45.65 | +1.69% | $7.46B | — | — | 8.5 | −40.7% |
| Clene | $4.48 | −1.77% | $58.0M | — | — | 294.5 | +233.3% |
| Median | 8.7 | 151.9 | 18.8 | +80.5% |